Abstract
A novel genomic inversion in Wiskott-Aldrich–associated autoinflammation
Highlights
We describe a patient with Wiskott-Aldrich syndrome (WAS) with a peculiar large genomic inversion presenting with multiple manifestations of immune dysregulation, in whom autoinflammatory manifestations improved after the use of anakinra (IL-1 receptor antagonist, Kineret)
When the patient was referred to our center, he was on adalimumab and low-dose CCS with a good control of bowel disease, but still showed severe manifestations of pyoderma gangrenosum (PG) on the upper limbs and in the perianal area (Fig 1, A; see Table E2 in this article’s Online Repository at www.jacionline.org)
FOR REV FOR REV FOR REV FOR REVPCR cycles 948C 3 min, 948C 30 s, 54.68C 30 s, 728C 1 min 3 40 cycles, 728C 10 min 948C 3 min, 948C 30 s, 54.68C 30 s, 728C 1 min 3 40 cycles, 728C 10 min 948C 3 min, 948C 30 s, 55.88C 30 s, 728C 1 min 3 40 cycles, 728C 10 min 948C 3 min, 948C 30 s, 55.88C 30 s, 728C 1 min 3 40 cycles, 728C 10 min
Summary
When the patient was referred to our center, he was on adalimumab and low-dose CCS with a good control of bowel disease, but still showed severe manifestations of PG on the upper limbs and in the perianal area (Fig 1, A; see Table E2 in this article’s Online Repository at www.jacionline.org). His parents signed informed consent for research investigations (protocol Tiget[06]). The rest of the authors declare that they have no relevant conflicts of interest
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
